Premium
FACILITATED IMMUNOGLOBULIN (FSCIG) USE IN PATIENTS WITH SECONDARY IMMUNODEFICIENCY DISEASES: TWO‐YEAR INTERIM RESULTS FROM THE FIGARO STUDY
Author(s) -
Dimou M,
Huscher D,
Hermann C,
Pittrow D,
Speletas M,
Borte M
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.18_2881
Subject(s) - medicine , tolerability , interim analysis , immunodeficiency , rituximab , primary immunodeficiency , pediatrics , lymphoma , adverse effect , clinical trial , immunology , disease , immune system
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom